The Pharma Data

SEPTEMBER 25, 2020

. Monte Rosa Therapeutics has raised $96m in Series B financing to support further develop of its pipeline of small-molecule protein degraders. The company, which was originally formed as a spinout from Cancer Research UK-funded research at the Institute of Cancer Research, specialises in targeted protein degradation.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Clinical Development Disease 40

Drug Target Review

JULY 23, 2024

Focusing on my time as Head of Research at Kymera, I’ve been fortunate to break new ground in drug discovery and development by advancing the science of targeted protein degradation (TPD) and progressing an industry leading pipeline to solve critical health problems that traditional medicines cannot address.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

The Pharma Data

DECEMBER 15, 2020

Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 NEW HAVEN, Conn.,

Targeted Protein Degradation 40

Targeted Protein Degradation Engineering Clinical Trials Disease 40

Drug Target Review

OCTOBER 4, 2023

Dual payload ADCs As effective as therapies have been in treating solid and haematological cancers, tumour heterogeneity and resistance remain major clinical challenges. To overcome these obstacles, combination therapy, which delivers multiple small molecules, has emerged as a potential solution. 1 , 33–43 (2018). 102 , 1–6 (2016).

Small Molecule 127

Small Molecule Drugs Immune Response Targeted Protein Degradation 127

LifeSciVC

FEBRUARY 5, 2025

However, in recent years, huge leaps have been made in drug discovery ranging from novel technologies unearthing new techniques for small molecule development to new modalities like targeted protein degradation that are beginning to open the door to a promising wave of transcription factor-directed therapeutic candidates.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67

LifeSciVC

OCTOBER 28, 2024

Today’s market likes products. As context, biotech business models have largely had two flavors for decades: asset-centric investments focused on specific product opportunities and platforms (discovery engines) designed to create new drugs based on novel modalities, technologies, or biological insights. Some worked and some didn’t.

Licensing 91

Licensing Licensing Marketing Targeted Protein Degradation 91